Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Isotope Labelled Efalizumab Biosimilar - Anti-ITGAL/CD11a mAb - Research Grade |
---|---|
Source | CAS 214745-43-4 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >95% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | MS |
Aliases /Synonyms | hu1124 |
Reference | PX-TA1040-SIL |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
Efalizumab is a recombinant monoclonal antibody to Human CD11A. Under the trade name Raptiva, it is a drug that was previously used to treat autoimmune diseases and was originally used to treat psoriasis. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and inhibits lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab has been associated with fatal brain infections.
Reviews
Il n’y a pas encore d’avis.